Pembrolizumab induced severe sclerodermoid reaction

Annals of Oncology

Volumn 28, Issue 2, 2017, Pages 432-433

  Shenoy, N ^a   Esplin, B ^a   Barbosa, N ^a   Wieland, C ^a   Thanarajasingam, U ^a   Markovic, S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; PEMBROLIZUMAB; PREDNISONE; STEROID; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; AGED; CANCER IMMUNOTHERAPY; CASE REPORT; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; LETTER; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; PNEUMONIA; PRIORITY JOURNAL; RADIODIAGNOSIS; RIGIDITY; SCLERODERMOID REACTION; SKIN BIOPSY; SKIN DISEASE; SKIN MANIFESTATION; SKINFOLD; TREATMENT DURATION; TREATMENT RESPONSE; CHEMICALLY INDUCED; MELANOMA; SYSTEMIC SCLEROSIS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; HUMANS; MALE; MELANOMA; SCLERODERMA, SYSTEMIC;

EID: 85019641607     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw543     Document Type: Letter

References (5)

1. Robert C, Ribas A, Wolchok JD et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109-1117.
2. Robert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.
3. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028.
4. Sul J, Blumenthal GM, Jiang X et al. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist 2016; 21: 643-650.
5. Chow LQ, Haddad R, Gupta S et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results fromthe phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016 September 19 [epub ahead of print], doi:10.1200/JCO.2016.68.1478.